GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (STU:D4S) » Definitions » Cyclically Adjusted Price-to-FCF

Daiichinkyo Co (STU:D4S) Cyclically Adjusted Price-to-FCF : 85.59 (As of May. 28, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Cyclically Adjusted Price-to-FCF?

As of today (2024-05-28), Daiichinkyo Co's current share price is €33.38. Daiichinkyo Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.39. Daiichinkyo Co's Cyclically Adjusted Price-to-FCF for today is 85.59.

The historical rank and industry rank for Daiichinkyo Co's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

STU:D4S' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 21.98   Med: 68.04   Max: 135.66
Current: 86.01

During the past years, Daiichinkyo Co's highest Cyclically Adjusted Price-to-FCF was 135.66. The lowest was 21.98. And the median was 68.04.

STU:D4S's Cyclically Adjusted Price-to-FCF is ranked worse than
79.81% of 312 companies
in the Drug Manufacturers industry
Industry Median: 32.27 vs STU:D4S: 86.01

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Daiichinkyo Co's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €-0.056. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €0.39 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Daiichinkyo Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Daiichinkyo Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Cyclically Adjusted Price-to-FCF Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.80 85.82 71.59 129.52 75.19

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.52 135.65 118.85 58.35 75.19

Competitive Comparison of Daiichinkyo Co's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Cyclically Adjusted Price-to-FCF falls into.



Daiichinkyo Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Daiichinkyo Co's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=33.38/0.39
=85.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiichinkyo Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Daiichinkyo Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.056/107.2000*107.2000
=-0.056

Current CPI (Mar. 2024) = 107.2000.

Daiichinkyo Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.016 98.000 0.018
201409 0.046 98.500 0.050
201412 0.066 97.900 0.072
201503 0.033 97.900 0.036
201506 -0.028 98.400 -0.031
201509 0.092 98.500 0.100
201512 0.062 98.100 0.068
201603 0.247 97.900 0.270
201606 0.107 98.100 0.117
201609 0.097 98.000 0.106
201612 -0.022 98.400 -0.024
201703 0.167 98.100 0.182
201706 -0.040 98.500 -0.044
201709 0.049 98.800 0.053
201712 0.057 99.400 0.061
201803 0.204 99.200 0.220
201806 -0.097 99.200 -0.105
201809 0.024 99.900 0.026
201812 0.017 99.700 0.018
201903 0.161 99.700 0.173
201906 0.269 99.800 0.289
201909 0.057 100.100 0.061
201912 0.089 100.500 0.095
202003 0.197 100.300 0.211
202006 0.072 99.900 0.077
202009 0.200 99.900 0.215
202012 0.052 99.300 0.056
202103 0.201 99.900 0.216
202106 -0.207 99.500 -0.223
202109 0.171 100.100 0.183
202112 0.208 100.100 0.223
202203 0.085 101.100 0.090
202206 -0.150 101.800 -0.158
202209 0.198 103.100 0.206
202212 0.067 104.100 0.069
202303 0.057 104.400 0.059
202306 -0.248 105.200 -0.253
202309 -0.135 106.200 -0.136
202312 2.017 106.800 2.025
202403 -0.056 107.200 -0.056

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Daiichinkyo Co  (STU:D4S) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Daiichinkyo Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (STU:D4S) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (STU:D4S) Headlines

No Headlines